MED64應(yīng)用手冊(cè)：人類干細(xì)胞來(lái)源的心肌細(xì)胞應(yīng)用

關(guān)鍵詞：
人類干細(xì)胞來(lái)源的心肌細(xì)胞 Human stem cell-derived cardiomyocytes (hSC-CMs) 搏動(dòng)頻率 beat frequency; 場(chǎng)電位時(shí)程 field potential duration (FPD)
慢性藥物作用 chronotropic drug effects; 藥物篩選 drug screening

人類干細(xì)胞來(lái)源的心肌細(xì)胞是制藥公司和科研機(jī)構(gòu)在研究中應(yīng)用得比較多的樣本。由于人類干細(xì)胞來(lái)源的心肌細(xì)胞具有和原代人類心肌細(xì)胞一樣的遺傳背景，它們的藥理學(xué)特性應(yīng)該非常相似，因此結(jié)合人類干細(xì)胞來(lái)源的心肌細(xì)胞與MED64多電極胞外記錄系統(tǒng)的平臺(tái)已成為了研究人類遺傳性心肌疾病模型和藥物篩選的主流。
只需要將hSC-CMs培養(yǎng)在MED記錄電極上，就可以從MED64系統(tǒng)中記錄和提取出基本的電生理參數(shù)，比如搏動(dòng)頻率、以場(chǎng)電位時(shí)程等。另外，由于電極的非侵入特性，穩(wěn)定的記錄可以持續(xù)非常長(zhǎng)的時(shí)間，因此慢性藥物的效果也能夠在MED64系統(tǒng)上進(jìn)行測(cè)量。不僅如此，MED64還可以使用任意電極輸出刺激來(lái)Pace hSC-CMs，因此可用來(lái)研究頻率依賴或使用依賴的藥物作用。

參考文獻(xiàn)：

1.Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ,Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers
DM, Robbins RC, Longaker MT, Wu JC.
Cell Stem Cell. 12(1):101-13 (2013)

2.Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.
Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC.
Sci Transl Med. 4:130 (2012)

3.A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
Yamazaki K, Hihara T, Taniguchi T, Kohmura N, Yoshinaga T, Ito M, Sawada K.
J Toxicol In Vitro. 26(2):335-342 (2011)

4.Usefulness of field potential as a marker of embryonic stem cell-derived cardiomyocytes, and endpoint analysis of embryonic stem cell test.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki T.
Toxicol Sci. 35(6):899-909 (2010)

5.Improvement of the embryonic stem cell test endpoint analysis by use of field potential detection.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki T.J Toxicol Sci. 35(5):619-29 (2010)

6.Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs.
Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N.Stem Cell Res. 4(3):201-13 (2010)